Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > 25% decrease in Egtifta sales

<< Previous

Bullboard Posts

Next >>

Comment by Mannequinon Apr 10, 2024 12:57pm

95 Views

Post# 35981497

RE:RE:RE:RE:RE:25% decrease in Egtifta sales

The invventory is their inventory on hand ready for sale at the insurers....so they bought more prior to prices rising. Now they need to load up again. It's like a car dealer inventory of vehicle days of inventory on hand. If it's low, they need more soon.

Trogarzon wrote: Listening back on the call it's the same language from Paul once again promissing deals and growing sales soon or later. They have until May 9. I felt that their CMO was rushing his answer and had enthousiasm in his remarks.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec